JPH0147447B2 - - Google Patents
Info
- Publication number
- JPH0147447B2 JPH0147447B2 JP55018725A JP1872580A JPH0147447B2 JP H0147447 B2 JPH0147447 B2 JP H0147447B2 JP 55018725 A JP55018725 A JP 55018725A JP 1872580 A JP1872580 A JP 1872580A JP H0147447 B2 JPH0147447 B2 JP H0147447B2
- Authority
- JP
- Japan
- Prior art keywords
- endorphin
- injection
- patients
- pain
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 27
- 101800005049 Beta-endorphin Proteins 0.000 claims description 25
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 24
- 238000002347 injection Methods 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000036407 pain Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 210000002330 subarachnoid space Anatomy 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- -1 Beta-endorphin Natural products 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229930195686 communin Natural products 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1872580A JPS56115722A (en) | 1980-02-18 | 1980-02-18 | Analgesic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1872580A JPS56115722A (en) | 1980-02-18 | 1980-02-18 | Analgesic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56115722A JPS56115722A (en) | 1981-09-11 |
| JPH0147447B2 true JPH0147447B2 (https=) | 1989-10-13 |
Family
ID=11979636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1872580A Granted JPS56115722A (en) | 1980-02-18 | 1980-02-18 | Analgesic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56115722A (https=) |
-
1980
- 1980-02-18 JP JP1872580A patent/JPS56115722A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56115722A (en) | 1981-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Friedman et al. | Ergotamine tolerance in patients with migraine | |
| Boddy et al. | The effects of pentobarbitone and pethidine on foetal breathing movements in sheep | |
| Madej et al. | Evaluation of “3 in 1” lumbar plexus block in patients having muscle biopsy | |
| Hankey et al. | Intrathecal baclofen for severe spasticity | |
| JP2001510794A (ja) | レボブピバカインとその使用 | |
| Rocke, DA, Wesley, AG, Pather, M., Calver, AD & Hariparsad | Morphine in tetanus-the management of sympathetic nervous system overactivity | |
| Adriani et al. | Some observations on the use of curare in the treatment of tetanus | |
| JPH0147447B2 (https=) | ||
| Robinson | Aspirin and the Adrenal Cortex | |
| Prakash et al. | A comparative study of bupivacaine 0.25% alone and with fentanyl or dexmedetomidine for percutaneous nephrolithotomy (PCNL) under epidural anaesthesia | |
| US4313937A (en) | Method for producing long-lasting analgesic effects of β-endorphin | |
| Engquist et al. | Cortisol, glucose, and hemodynamic responses to surgery after naloxone administration | |
| Marshall et al. | Analgesia for burns dressing using methoxyflurane | |
| SU1600775A1 (ru) | Способ лечени ишемического церебрального инсульта в остром периоде | |
| Gökçek et al. | Cardiac arrest after trigger point injection | |
| Gaudy et al. | Effect of a new analeptic drug, almitrine, on fentanyl-induced respiratory depression and analgesia in man | |
| Cholewa et al. | Effects of naloxone on ethanol-induced coma | |
| Gready et al. | Continuous Caudal Anesthesia in Obstetrics: Preliminary Report | |
| Mishra et al. | A clinical comparison between bupivacaine midazolam combination and bupivacaine plain in brachial plexus block by supraclavicular approach | |
| Edwards et al. | Diazepam and local analgesia for lumbar air encephalography | |
| Kelly | Progress in anxiety states | |
| Anzil | Comparison of intrathecal nalbuphine and fentanyl as an adjuvant to hyperbaric bupivacine for spinal anaesthesia in infraumbilical surgeries: A prospective randomized, double blind study | |
| Kumar et al. | Comparative study of outcome in epidural bupivacaine with buprenorphine and bupivacaine with fentanyl in lower limb surgeries | |
| SIGNS | Altered Mental Status in a Patient With Substance Use Disorder | |
| SU1623655A1 (ru) | Способ лечени церебрального инсульта |